NAO.VNS™
Drug-Resistant Epilepsy (via Vagus Nerve Stimulation)
Key Facts
About Synergia Medical
Synergia Medical is a private, clinical-stage medical device company pioneering an optoelectronic neuromodulation platform. Its lead product, NAO.VNS™, is a Vagus Nerve Stimulation (VNS) device for drug-resistant epilepsy, which has successfully completed initial safety evaluations in a first-in-human study (AURORA) with five patients implanted. The company's technology promises full MRI compatibility, electromagnetic interference (EMI) immunity, extended battery life, and enhanced cybersecurity, positioning it to address significant unmet needs in the neuromodulation market. Backed by regional and European Union funding, Synergia is preparing for pivotal trials to seek FDA and CE Mark approvals.
View full company profile